BPI, Human, ELISA kit – 2 x 96 det. - HK314-02
Quantity
2 x 96 det.
Catalog #
HK314-02
1.127,00 €
The antimicrobial protein BPI (Bactericidal Permeability Increasing protein) is a 55 kDa protein found in the primary (azurophilic) granules of human neutrophils and has also been detected on surface of neutrophils, small intestinal and oral epithelial cells. BPI is a bactericidal compound that is present in polymorphonuclear cells (PMN) and in lower levels in the specific granules of eosinophils. BPI possesses high affinity toward the lipid A region of lipopolysaccharides (LPS) that comprise the outer leaflet of the gram-negative bacterial outer membrane. Binding of BPI to the lipid A moiety of LPS exerts multiple anti-infective activities against gram-negative bacteria: 1) cytotoxicity via sequential damage to bacterial outer and inner lipid membranes, 2) neutralization of gram-negative bacterial LPS, 3) opsonization of bacteria to enhance phagocytosis by neutrophils. Airway epithelial cells constitutively express the BPI gene and produce the BPI protein and, therefore, BPI may be a critical determinant in the development of LPS-triggered airway disease. Inflammation induced by LPS possibly contributes to the development of rapid airflow decline, a serious and often fatal complication of hematopoietic cell transplantation. Furthermore, a 21 kDa bioactive recombinant fragment of BPI, rBPI21, was shown to confer a survival advantage against invasive pneumococcal disease by binding to the gram-positive bacterial pathogen, pneumolysin. In plasma of healthy individuals BPI is present at levels of <0.5 ng/ml, which increases approximately 10-fold during acute phase responses.
| Datasheet URL | https://www.hycultbiotech.com/wp-content/uploads/2022/06/HK314-0513.pdf |
|---|---|
| Quantity | 2x96det. |
| Quantity | 2 x 96 det. |
| Standard range | 100-25,000 pg/ml |
| Detection level | 250 pg/ml |
| Working volume | 100 µl/well |
| Species | human |
| Application | The human BPI ELISA kit is to be used for the in vitro quantitative determination of human BPI in cell culture medium, plasma, wound fluid and bronchoalveolar lavage fluid. |
| Principle | The human BPI ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 4½ hours. The efficient format of 2 plates with twelve disposable 8-well strips allows free choice of batch size for the assay. Samples and standards are captured by a solid bound specific antibody. Biotinylated tracer antibody will bind to captured human BPI. Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody. Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of oxalic acid. The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human BPI standards (log). The human BPI concentration of samples, which are run concurrently with the standards, can be determined from the standard curve. |
| Storage and stability | Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least six months. |
| Precautions | For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use or derivation of this product. |
| References | 1. Espinoza, J et al; Antimicrobial peptides in amniotic fluid: defensins, calprotectin and
bacterial/permeability-increasing protein in patients with microbial invasion of the
amniotic cavity, intra-amniotic inflammation, preterm labor and premature rupture of
membranes. J Matern Fetal Neonatal Med 2003, 13: 2 2. Maris, N et al; Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005, 172: 878 3. Gubern, C et al; Natural antibiotics and insulin sensitivity, the role of bactericidal/permeability-increasing protein. Diabetes 2006, 55: 216 4. Manco, M et al; Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 2007, 92: 483 5. Strunk, T et al; Reduced levels of antimicrobial proteins and peptides in human cord blood plasma. Arch Dis Child Fetal Neonatal Ed 2009, 94: F230 |
| Disease | Infectious diseases |
| Application assays: | The human BPI ELISA kit is to be used for the in vitro quantitative determination of human BPI in cell culture medium, plasma, wound fluid and bronchoalveolar lavage fluid. |
|---|---|
| Principle: | The human BPI ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 4½ hours. The efficient format of 2 plates with twelve disposable 8-well strips allows free choice of batch size for the assay. Samples and standards are captured by a solid bound specific antibody. Biotinylated tracer antibody will bind to captured human BPI. Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody. Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of oxalic acid. The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human BPI standards (log). The human BPI concentration of samples, which are run concurrently with the standards, can be determined from the standard curve. |
Diese Artikel könnten Ihnen eventuell auch gefallen!
